Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | JAK2 LOH JAK2 inact mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| JAK2 LOH JAK2 inact mut | melanoma | predicted - sensitive | VSV-delta51 | Preclinical - Patient cell culture | Actionable | In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, VSV-delta51, in culture (PMID: 33593882). | 33593882 | |
| JAK2 LOH JAK2 inact mut | melanoma | predicted - sensitive | HSV1-dICP0 | Preclinical - Patient cell culture | Actionable | In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, HSV1-dICP0, in culture (PMID: 33593882). | 33593882 |